Ostarine, also referred to as MK-2866, GTX 024, or Enobosarm, is the most prominent and extensively researched selective androgen receptor modulator (SARM). It made its appearance in the late 1990s, initially introduced as a potential remedy for osteoporosis and specific diseases leading to insulin resistance, muscle deterioration, and muscle loss. Currently, Ostarine is in phase II clinical trials and stands as the nearest SARM to receive medical treatment approval.